BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27486079)

  • 1. Discovery of Novel Mycobacterial DNA Gyrase B Inhibitors: In Silico and In Vitro Biological Evaluation.
    Saxena S; Renuka J; Yogeeswari P; Sriram D
    Mol Inform; 2014 Sep; 33(9):597-609. PubMed ID: 27486079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.
    Jeankumar VU; Renuka J; Pulla VK; Soni V; Sridevi JP; Suryadevara P; Shravan M; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Int J Antimicrob Agents; 2014 Mar; 43(3):269-78. PubMed ID: 24434114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies.
    Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D
    Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel inhibitors against Mycobacterium tuberculosis L-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening.
    Saxena S; Devi PB; Soni V; Yogeeswari P; Sriram D
    J Mol Graph Model; 2014 Feb; 47():37-43. PubMed ID: 24316937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S; Abdullah M; Sriram D; Guruprasad L
    J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel Pseudomonas aeruginosa DNA gyrase B inhibitors.
    Jogula S; Krishna VS; Meda N; Balraju V; Sriram D
    Bioorg Chem; 2020 Jul; 100():103905. PubMed ID: 32388436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
    Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM
    J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis.
    Kashyap A; Singh PK; Satpati S; Verma H; Silakari O
    J Cell Biochem; 2019 Mar; 120(3):3149-3159. PubMed ID: 30191589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore-based virtual screening, molecular docking and molecular dynamics studies.
    Islam MA; Pillay TS
    Chem Biol Drug Des; 2017 Aug; 90(2):282-296. PubMed ID: 28109130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis.
    Shirude PS; Madhavapeddi P; Tucker JA; Murugan K; Patil V; Basavarajappa H; Raichurkar AV; Humnabadkar V; Hussein S; Sharma S; Ramya VK; Narayan CB; Balganesh TS; Sambandamurthy VK
    ACS Chem Biol; 2013 Mar; 8(3):519-23. PubMed ID: 23268609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Guided Discovery of Antitubercular Agents That Target the Gyrase ATPase Domain.
    Jeankumar VU; Saxena S; Vats R; Reshma RS; Janupally R; Kulkarni P; Yogeeswari P; Sriram D
    ChemMedChem; 2016 Mar; 11(5):539-48. PubMed ID: 26805396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
    Maharaj Y; Soliman ME
    Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
    Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
    J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
    Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioisosteric Design Identifies Inhibitors of
    Kamsri B; Pakamwong B; Thongdee P; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Goudar KE; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2023 May; 63(9):2707-2718. PubMed ID: 37074047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase.
    Petersen GO; Saxena S; Renuka J; Soni V; Yogeeswari P; Santos DS; Bizarro CV; Sriram D
    J Mol Graph Model; 2015 Jul; 60():124-31. PubMed ID: 26043661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.